#Japan #Tokyo #MSC Therapy #HELENE BIO Group #Omotesando Helene Clinic

A Breakthrough Study on High-Dose MSC Treatment

Recently, the Omotesando Helene Clinic, located in Minato Ward, Tokyo, announced the publication of a groundbreaking study concerning the long-term safety of high-dose intravenous mesenchymal stem cell (MSC) therapy. Conducted by Dr. Takaaki Matsuoka and Dr. Nana Kobayashi, the research paper titled "Cardiovascular Event Surveillance Following High-Dose Intravenous Mesenchymal Stem Cell Therapy: A Single-Center Real-World Observational Study" has been featured in the prestigious International Journal of Translational Medicine.

The Research Significance

This study is particularly significant as it goes beyond theoretical insights and delves into real-world clinical data spanning from January 2014 to December 2023. The aim was to track major adverse cardiac and cerebrovascular events (MACCE) post high-dose MSC infusion. The researchers meticulously analyzed patient records to assess the long-term cardiovascular and cerebrovascular safety of this innovative treatment.

Remarkably, the study concluded that there was no evident excess risk of major cardiac or cerebrovascular events following the administration of high-dose intravenous MSCs. However, given that this was a retrospective observational study with a limited number of events, the authors advocate for larger-scale prospective studies in the future to further evaluate long-term safety.

Focus on Clinical Data

Dr. Matsuoka stated, “At Omotesando Helene Clinic, we don’t just accrue clinical experience; we prioritize validating the data we collect. This paper's publication demonstrates our commitment to provide better healthcare to patients from both clinical and research perspectives. Moreover, as part of the HELENE BIO Group's Tokyo clinical hub, we aim to scientifically consolidate the insights obtained from actual clinical practices to contribute to the advancement of regenerative medicine and ATMP sectors.”

The study does not aim to demonstrate the treatment’s efficacy; rather, it is focused on providing valuable insights into the long-term safety of regenerative medicine based on concrete clinical data.

Details of the Publication

• - Title: Cardiovascular Event Surveillance Following High-Dose Intravenous Mesenchymal Stem Cell Therapy: A Single-Center Real-World Observational Study
• - Authors: Dr. Takaaki Matsuoka, Dr. Nana Kobayashi
• - Published in: International Journal of Translational Medicine
• - Publication Date: March 30, 2026
• - DOI: 10.3390/ijtm6020015

Continuation of Academic Activities

The Omotesando Helene Clinic is committed to continuous academic activities in the field of regenerative medicine, including MSC research. They actively validate clinical data, present research findings, and participate in conferences to share insights obtained from their work. Past endeavors have covered a range of topics including the safety of MSC treatments, cell culture technology, exosomes, and quality of life evaluations, further solidifying their dedication to enhancing patient care.

About HELENE BIO Group

HELENE BIO Group represents a consortium that integrates clinical, data, cell processing, and research development within the cell therapy and ATMP landscapes. Their network extends across various regions such as Tokyo, the UK, and the UAE, aiming to link real-world clinical insights to the advancement, quality control, standardization, and future regulatory compliance of cell therapies. The Omotesando Helene Clinic serves as the Tokyo clinical hub of this network, accumulating real-world data and knowledge to improve and share academic findings related to regenerative medicine.

Conclusion

As the Omotesando Helene Clinic continues to advance in regenerative medicine, they are focused on pursuing the potential of such treatments while maintaining a strong commitment to responsible information dissemination and academic activities. The publication of this timely study marks just one milestone in their ongoing journey to enhance the quality and safety of healthcare for their patients.